Friday, 6 November 2026European Markets

SAINT GOBAIN And SERGEFERRARI GROUP Have A High Dividend Yield And Return On Equity In The Building Products & Equipment Industry.

Loading stream...

(vianews) - saint gobain (sgo.pa) is among this list of stock assets with the highest dividend rate and return on equity on the building products & equipment industry.

financial asset price forward dividend yield return on equity
saint gobain (sgo.pa) €50.48 3.83% 14.01%
sergeferrari group (sefer.pa) €14.12 2.88% 13.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. saint gobain (sgo.pa)

3.83% forward dividend yield and 14.01% return on equity

compagnie de saint-gobain s.a. designs, manufactures, and distributes materials and solutions for wellbeing worldwide. it operates through five segments: high performance solutions; northern europe; southern europe – middle east (me) & africa; americas; and asia-pacific. the company offers glazing solutions for buildings and cars under the saint-gobain, glasssolutions, vetrotech, and sageglass brands; plaster-based products for construction and renovation markets under the placo, rigips, and gyproc brands; ceilings under the ecophon, certainteed, eurocoustic, sonex, or vinh tuong brands; and insulation solutions for a range of applications, such as construction, engine compartments, vehicle interiors, household appliances, and photovoltaic panels under the isover, certainteed, and izocam brands. it also offers mortars and building chemicals under the weber brand; exterior products comprising asphalt and composite shingles, roll roofing systems, and accessories; and pipes under the pam brand, as well as designs, imports, and distributes instant adhesives, sealants, and silicones. in addition, the company provides interior systems, interior and exterior insulation, cladding, floor coverings, façades and lightweight structures, waterproofing, roofing solutions, pre-assembly, and prefabrication solutions; high performance materials; glass for buildings; plasterboard; and interior glass products. further, it distributes heavy building materials; plumbing, heating, and sanitary products; timbers and panels; civil engineering products; ceramic tiles; and site equipment and tools. the company was founded in 1665 and is headquartered in courbevoie, france.

earnings per share

as for profitability, saint gobain has a trailing twelve months eps of €5.8.

pe ratio

saint gobain has a trailing twelve months price to earnings ratio of 8.7. meaning, the purchaser of the share is investing €8.7 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.01%.

revenue growth

year-on-year quarterly revenue growth grew by 16.7%, now sitting on 51.2b for the twelve trailing months.

yearly top and bottom value

saint gobain's stock is valued at €50.48 at 02:40 est, way under its 52-week high of €58.53 and way higher than its 52-week low of €35.18.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, saint gobain's stock is considered to be oversold (<=20).

more news about saint gobain.

2. sergeferrari group (sefer.pa)

2.88% forward dividend yield and 13.51% return on equity

sergeferrari group sa designs, manufactures, and distributes flexible composite materials in france and internationally. the company offers solutions for indoor and outdoor blind, and terrace blind and awning; tensile roof, shading structure, and big top; indoor and outdoor acoustic treatment; bioclimatic facade; building construction and renovation; and waterproof breathable membrane applications. it also provides products and solutions for modular structure, visual communication for printed advertisement, protection and environment, and yachting applications. in addition, the company offers sling seats for outdoor and contract furniture and upholstery for indoor and outdoor furniture. further, it provides antiviral technology on surfaces dedicated for indoor applications. the company was founded in 1973 and is headquartered in saint-jean-de-soudain, france.

earnings per share

as for profitability, sergeferrari group has a trailing twelve months eps of €0.91.

pe ratio

sergeferrari group has a trailing twelve months price to earnings ratio of 15.52. meaning, the purchaser of the share is investing €15.52 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.51%.

volatility

sergeferrari group's last week, last month's, and last quarter's current intraday variation average was a negative 0.07%, a negative 0.12%, and a positive 2.30%.

sergeferrari group's highest amplitude of average volatility was 1.07% (last week), 2.31% (last month), and 2.30% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 19.5%, now sitting on 338.7m for the twelve trailing months.

volume

today's last reported volume for sergeferrari group is 2028 which is 83.21% below its average volume of 12083.

more news about sergeferrari group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com